CD47-Reduced Viral Vector Production for Phagocyte Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing viral vectors face challenges in efficiently transducing professional phagocytes and antigen-presenting cells due to the presence of CD47 molecules on their surface, which can trigger immune responses and hinder gene transfer efficiency.
Innovation Solution
Genetically engineering cells to decrease or eliminate CD47 expression on the surface of viral particle producer cells, resulting in CD47-free viral particles that enhance transduction efficiency and immune stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD47 molecules are present on viral particle surface, then immune cell sensing is reduced, but transduction efficiency of professional phagocytes and antigen-presenting cells decreases
Solution Approach 1:
The patent applies local quality by differentiating the CD47 expression requirements for different cell types. Producer cells maintain CD47 expression for immune evasion, while target cells (professional phagocytes and antigen-presenting cells) require CD47 downregulation for efficient transduction. This spatial and functional differentiation resolves the contradiction between immune evasion and transduction efficiency.
Solution Approach 2:
The patent employs dynamic control of CD47 expression levels at different stages of the viral vector process. CD47 is expressed during viral particle production for immune evasion, then dynamically reduced or eliminated on the surface of produced viral particles to enable efficient phagocytosis and transduction of target cells. This temporal dynamics resolves the contradiction.
2Productivity
If CD47 expression is decreased on producer cells, then transduction efficiency into phagocytes improves, but immune response stimulation decreases
Solution Approach 1:
The patent segments the viral vector system into two distinct components: producer cells that maintain CD47 expression for immune evasion during production, and viral particles with reduced CD47 for efficient target cell transduction. This segmentation allows each component to optimize its function without compromising the other.
Solution Approach 2:
The patent applies preliminary action by pre-regulating CD47 expression levels in producer cells before viral particle production. This preliminary control ensures that viral particles are produced with appropriate CD47 levels that will facilitate subsequent phagocytosis and transduction, while the producer cells themselves maintain immune evasion capabilities during the production phase.
Data Source
AI summary
An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of CD47 on the surface of the cell.